Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations
Roflumilast is given as an add-on to inhalation medication in patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis. Animal experiments have documented deleterious effects of roflumilast in bacterial infections, but trials have not reported the risk of bacterial infection...
Main Authors: | Imane Achir Alispahic, Rikke Sørensen, Josefin Eklöf, Pradeesh Sivapalan, Anders Løkke, Niels Seersholm, Jakob Hedemark Vestergaard, Jens-Ulrik Stæhr Jensen |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/5/1442 |
Similar Items
-
Longstanding tracheobronchomalacia: A forgotten cause of severe cough and its response to roflumilast
by: Veronica Ann Varney, et al.
Published: (2020-01-01) -
Roflumilast is effective in reducing COPD related exacerbations and improving CAT score
by: Biagio Polla
Published: (2015-08-01) -
Roflumilast is safe and effective in improving symptoms and lung function in severe COPD
by: Matteo Bonini, et al.
Published: (2015-08-01) -
Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD
by: Watz H, et al.
Published: (2018-03-01) -
Significant gas-exchange improvements reported after roflumilast in two cases of severe COPD
by: Bruno Sposato
Published: (2015-08-01)